EQS-News: GeoVax to Participate in BIO International Convention 2025

ATLANTA, GA - June 12, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today announced that company representatives will attend the 2025 BIO International Convention being held June 16-19, 2025 at the Boston Convention and Exhibition Center in Boston, Massachusetts.

The BIO International Convention is the world’s largest gathering of the biotechnology industry, attracting thousands of biotechnology and pharmaceutical executives from around the globe. The event provides an ideal venue for companies to engage with potential partners, investors, and policymakers.

During the convention, GeoVax will participate in business development and partnering meetings to discuss its expanding pipeline of infectious disease and cancer immunotherapies, including GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine targeting Mpox and smallpox; GEO-CM04S1, a multi-antigen COVID-19 vaccine candidate; and Gedeptin®, a gene-directed enzyme prodrug therapy for the treatment of solid tumors.

GeoVax’s participation at BIO 2025 supports its broader business development strategy, including ongoing efforts to establish strategic partnerships, expand manufacturing capabilities, and align with public and private sector priorities in pandemic preparedness, oncology, and biodefense.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.

Company Contact:
info@geovax.com
678-384-7220 

Investor Relations
geovax@precisionaq.com
212-698-8696

Contact: Media Contact:
Jessica Starman
media@elev8newmedia.com

View the original release on www.newmediawire.com